Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new drug safely control eczema over the long haul?

NCT ID NCT07734415

Disease control Sponsor: Inmagene LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial is investigating whether long-term use of an experimental drug called IMG-007 can safely control moderate-to-severe eczema (atopic dermatitis). The study enrolls people who have already completed a previous IMG-007 trial and will receive the drug as a shot under the skin. Researchers are monitoring for side effects and checking how well the drug keeps eczema in check over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an experimental drug called IMG-007
What this could lead to
If it works, this could point toward a long-term treatment option for people with moderate-to-severe eczema.
What could go wrong
This is an early-stage extension study, so the drug's long-term safety and effectiveness are still unproven. Side effects may emerge with longer use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Enrolling by invitation participants with moderate to severe AD who have completed IMG-007-203

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema dermatitis Eczema immune system disorder skin disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis Atopic dermatitis (eczema) Eczema

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    23 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Inmagene Site 1

    Lancaster, California, 93534, United States

  • Inmagene Site 10

    Fargo, North Dakota, 58103, United States

  • Inmagene Site 11

    Woodbury, New York, 11797, United States

  • Inmagene Site 12

    Anderson, South Carolina, 29621, United States

  • Inmagene Site 13

    Mississauga, Ontario, L4Y 4C5, Canada

  • Inmagene Site 14

    Montreal, Quebec, H2X 2V1, Canada

  • Inmagene Site 15

    Surrey, British Columbia, V3R 6A7, Canada

  • Inmagene Site 16

    Saskatoon, Saskatchewan, S7K 2C1, Canada

  • Inmagene Site 17

    Greater Sudbury, Ontario, P3C 1X8, Canada

  • Inmagene Site 18

    North Bay, Ontario, P1B 3Z7, Canada

  • Inmagene Site 19

    Ocala, Florida, 34470, United States

  • Inmagene Site 2

    Rolling Meadows, Illinois, 60008, United States

  • Inmagene Site 20

    Charlotte, North Carolina, 28277, United States

  • Inmagene Site 21

    New York, New York, 10029, United States

  • Inmagene Site 22

    Vancouver, British Columbia, V6H 4B1, Canada

  • Inmagene Site 23

    Los Angeles, California, 90095, United States

  • Inmagene Site 3

    Portland, Oregon, 97210, United States

  • Inmagene Site 4

    Tampa, Florida, 33609, United States

  • Inmagene Site 5

    Mayfield Heights, Ohio, 44124, United States

  • Inmagene Site 6

    Kew Gardens, New York, 11415, United States

  • Inmagene Site 7

    Burien, Washington, 698168, United States

  • Inmagene Site 8

    Southlake, Texas, 76092, United States

  • Inmagene Site 9

    Columbus, Ohio, 43213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.